Leiden, NL - Monday, 5 December 2011

ZoBio BV (www.zobio.com) and Quantum Tessera Consulting, LLC (www.quantumtessera.com) have entered into a partnership where Quantum Tessera will act as the exclusive representative for ZoBio in North America. This partnership allows ZoBio to better serve existing customers and provide more immediate services for new customers. ZoBio specifically selected Quantum Tessera due to the experience, expertise and creativity of its Chief Scientific Officer, Dr. Edward R. Zartler. The complementary nature will enhance ZoBio’s market leading offerings in fee for service Fragment-based Drug Discovery (FBDD).  In addition to its industry leading, proprietary TINS (Target-Immobilized NMR Screening) methodology, ZoBio offers a range of biophysical methods to enable FBDD on today’s most challenging targets. Dr. Zartler’s more than 10 years of experience in large pharma settings will enhance ZoBio’s ability to undertake deeper projects covering a greater portion of the drug discovery pipeline. Gregg Siegal, Chief Scientific Officer of ZoBio said “We are excited about the creation of the partnership with Dr. Zartler as we feel this will provide us deeper insight into the needs of our customers”.  Teddy Zartler feels “this partnership allows both companies to continue to deliver industry leading services to its customers.”

About Quantum Tessera Consulting:
Quantum Tessera Consulting offers a wide range of services to its customers with a strong focus on FBDD.  Dr. Zartler has over a decade of experience in the pharmaceutical industry.  Dr. Zartler is an internationally recognized expert in FBDD, haven spoken on three continents about FBDD, edited the book Fragment-based Drug Discovery: A Practical Approach, and co-founded the popular blog Practical Fragments.

About ZoBio BV:
Starting with its core TINS (Target Immobilized NMR Screening) fragment screening technology, ZoBio provides an array of biophysics services to support fragment-based drug discovery. These services form an integrated pipeline that includes fragment discovery, validation/characterisation by orthogonal methods such as SPR and NMR-based structural biology services. ZoBio has used its cutting edge capabilities to discovery fragment inhibitors for variety of targets including kinases, protein-protein interaction, anti-virals and membrane proteins such as GPCRs and ligand gated ion channels.
For more information visit www.zobio.com